C-X-C motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC

Lung Cancer

Volumn 81, Issue 1, 2013, Pages 123-129

  Uzunoglu, Faik Güntac ^a   Yavari, Neda ^a   Bohn, Benjamin Alexander ^a   Nentwich, Michael Fabian ^a   Reeh, Matthias ^a   Pantel, Klaus ^a   Perez, Daniel ^a   Tsui, Tung Yu ^a   Bockhorn, Maximilian ^a   Mann, Oliver ^a   Izbicki, Jakob Robert ^a   Wikman, Harriet ^a   Vashist, Yogesh Kumar ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiogenesis; C X C motif receptor 2; Endostatin; Lung cancer; Polymorphisms; Proteinase activated receptor 1; Survival

Indexed keywords

CXC MOTIF RECEPTOR 2; ENDOSTATIN; GENOMIC DNA; PROTEINASE ACTIVATED RECEPTOR 1; RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CAPILLARY ELECTROPHORESIS; CAUCASIAN; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA EXTRACTION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LEUKOCYTE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; ENDOSTATINS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, PAR-1; RECEPTORS, INTERLEUKIN-8B; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84878984671     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.03.007     Document Type: Article

References (40)

1. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
2. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233-269.
3. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
4. Fontanini G., Bigini D., Vignati S., Basolo F., Mussi A., Lucchi M., et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995, 177:57-63.
5. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
6. Macchiarini P., Fontanini G., Hardin M.J., Squartini F., Angeletti C.A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992, 340:145-146.
7. Meert A.P., Paesmans M., Martin B., Delmotte P., Berghmans T., Verdebout J.M., et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002, 87:694-701.
8. O'Byrne K.J., Koukourakis M.I., Giatromanolaki A., Cox G., Turley H., Steward W.P., et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000, 82:1427-1432.
9. Reinmuth N., Parikh A.A., Ahmad S.A., Liu W., Stoeltzing O., Fan F., et al. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 2003, 60:199-207.
10. Herbst R.S., Onn A., Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005, 23:3243-3256.
11. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
12. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21:1804-1809.
13. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
14. Ellis L.M., Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008, 14:6371-6375.
15. Loges S., Schmidt T., Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010, 1:12-25.
16. Teicher B.A. Antiangiogenic agents and targets: a perspective. Biochem Pharmacol 2011, 81:6-12.
17. Goldstraw P., Ball D., Jett J.R., Le Chevalier T., Lim E., Nicholson A.G., et al. Non-small-cell lung cancer. The Lancet 2011, 378:1727-1740.
18. Herbst R.S., Sun Y., Eberhardt W.E., Germonpre P., Saijo N., Zhou C., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11:619-626.
19. Coate L.E., John T., Tsao M.S., Shepherd F.A. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009, 10:1001-1010.
20. Oldenhuis C.N., Oosting S.F., Gietema J.A., de Vries E.G. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008, 44:946-953.
21. Van Ness B., Ramos C., Haznadar M., Hoering A., Haessler J., Crowley J., et al. Genomic variation in myeloma: design, content, and initial application of the bank on a cure SNP panel to detect associations with progression-free survival. BMC Med 2008, 6:26.
22. Uzunoglu F.G., Kaufmann C., Wikman H., Gungor C., Bohn B.A., Nentwich M.F., et al. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer. Ann Surg Oncol 2012, 19:2159-2168.
23. Schneider B.P., Shen F., Miller K.D. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol 2012, 13:e427-e436.
24. Pallaud C.M.R., Juhasz E., Szima B., Yu C.-J., Burdaeva O., Orlov S., et al. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of 1st-line bevacizumab+chemotherapy in non-squamous non-small-cell lung cancer (NS-NSCLC). Ann Oncol 2012, 23(Suppl. 9):ix400-ix446.
25. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
26. Italiano J.E., Richardson J.L., Patel-Hett S., Battinelli E., Zaslavsky A., Short S., et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111:1227-1233.
27. Ma L., Elliott S.N., Cirino G., Buret A., Ignarro L.J., Wallace J.L. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A 2001, 98:6470-6475.
28. Ma L., Perini R., McKnight W., Dicay M., Klein A., Hollenberg M.D., et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A 2005, 102:216-220.
29. Pinedo H.M., Verheul H.M., D'Amato R.J., Folkman J. Involvement of platelets in tumour angiogenesis?. Lancet 1998, 352:1775-1777.
30. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
31. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072.
32. Sobin L.H., Gospodarowicz M.K., Wittekind C. International union against cancer. TNM classification of malignant tumours 2010, Wiley-Blackwell, Chichester, West Sussex, UK; Hoboken, NJ. 7th ed.
33. Marte Eilertsen I.P., Andersen S., Martinez I., Donnem T., Busund L.-T., Bremnes R.M. In NSCLC VEGF - a response to hypoxia may differ between squamous cell and adenocarcinoma histology. Anticancer Res 2012, 32:4729-4736.
34. Langer C.J., Besse B., Gualberto A., Brambilla E., Soria J.C. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:5311-5320.
35. Renzoni E., Lympany P., Sestini P., Pantelidis P., Wells A., Black C., et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000, 43:1633-1640.
36. Snoussi K., Mahfoudh W., Bouaouina N., Fekih M., Khairi H., Helal A.N., et al. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer 2010, 10:283.
37. Dupont A., Fontana P., Bachelot-Loza C., Reny J.L., Bieche I., Desvard F., et al. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 2003, 101:1833-1840.
38. Lurje G., Husain H., Power D.G., Yang D., Groshen S., Pohl A., et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol 2010, 21:78-86.
39. Lurje G., Leers J.M., Pohl A., Oezcelik A., Zhang W., Ayazi S., et al. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg 2010, 251:857-864.
40. Iughetti P., Suzuki O., Godoi P.H., Alves V.A., Sertie A.L., Zorick T., et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 2001, 61:7375-7378.